FGen
- Founded in: 2011
- Number of employees: 10
- Country: Switzerland
- Website: FGen.ch
Which input provides your business model/core technology towards a bio-based economy?
FGen develops and optimizes microbial strains (bacteria, yeasts, and fungi) by combining biological engineering, such as synthetic biology or non-GMO methods, with a proprietary high throughput screening platform. The constructed microbes find application in bio-based production, in the food and feed sector, in agriculture, or are used as probiotics.
Which market/clients do you address and which short-term/long-term goals do you have?
FGen collaborates as contract research organization with partners from industrial biotech, life sciences, and pharma, and has a successful track record in industrial strain development and improvement. The main goals of the company are to enlarge its service activities and in the medium term to develop proprietary microbes for specific applications.
What makes your approach unique compared to other stakeholders in the field?
FGen has developed and commercialized the nanoliter-reactor screening platform that enables the analysis of cell libraries at rates of up to 1 million clones per day under bioprocess and application relevant conditions. The technology therefore not only surpasses the throughput of current methods by orders of magnitude but also ensures that strain traits are maintained during scale-up and production.
You can meet FGen at EFIB in Brussels on 30 September – 2 October 2019.